Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives

被引:23
|
作者
Zhang, Zhening [1 ]
Xie, Tong [1 ]
Zhang, Xiaotian [1 ]
Qi, Changsong [1 ]
Shen, Lin [1 ]
Peng, Zhi [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing 100142, Peoples R China
关键词
Biomarker; gastric cancer; gastroesophageal junction cancer; immune checkpoint inhibitors; immunotherapy; safety; MISMATCH REPAIR DEFICIENCY; EPSTEIN-BARR-VIRUS; PD-1; BLOCKADE; DOUBLE-BLIND; EFFICACY; ADENOCARCINOMA; CAPECITABINE; NIVOLUMAB; THERAPY; SAFETY;
D O I
10.21147/j.issn.1000-9604.2020.03.02
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the application of conventional therapies, the prognosis of advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer therapy. Emerging evidence support the feasibility of programmed cell death-1 (PD-1) and its ligand (PD-L1) inhibition in chemo-refractory GC/GEJC. Nivolumab and pembrolizumab have initially been approved in Japan and United States, respectively for the third-line treatment of progressive GC or GEJC. In March 2020, nivolumab has also been licensed in China for treating advanced GC/GEJC who received >= 2 lines of systemic therapies. Current studies are moving forward to the first-line application or focusing on combination strategies, though data are insufficient and disputable. In this review, we summarize the recently reported and ongoing clinical trials in ICIs for advanced GC/GEJC. Molecular characteristics and clinical implications of different tumor subtypes are also reviewed. We further discuss the safety profile and biomarkers for predicting the response of ICIs, which has guiding values in clinical practice.
引用
收藏
页码:287 / 302
页数:16
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
    Zhening Zhang
    Tong Xie
    Xiaotian Zhang
    Changsong Qi
    Lin Shen
    Zhi Peng
    [J]. Chinese Journal of Cancer Research, 2020, 32 (03) : 287 - 302
  • [2] Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
    Rebuzzi, Sara Elena
    Rescigno, Pasquale
    Catalano, Fabio
    Mollica, Veronica
    Vogl, Ursula Maria
    Marandino, Laura
    Massari, Francesco
    Mestre, Ricardo Pereira
    Zanardi, Elisa
    Signori, Alessio
    Buti, Sebastiano
    Bauckneht, Matteo
    Gillessen, Silke
    Banna, Giuseppe Luigi
    Fornarini, Giuseppe
    [J]. CANCERS, 2022, 14 (05)
  • [3] Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives
    Daisuke Takahari
    Izuma Nakayama
    [J]. International Journal of Clinical Oncology, 2023, 28 : 1431 - 1441
  • [4] Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives
    Takahari, Daisuke
    Nakayama, Izuma
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (11) : 1431 - 1441
  • [5] Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
    Chenard-Poirier, Maxime
    Smyth, Elizabeth C.
    [J]. DRUGS, 2019, 79 (01) : 1 - 10
  • [6] Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
    Maxime Chénard-Poirier
    Elizabeth C. Smyth
    [J]. Drugs, 2019, 79 : 1 - 10
  • [7] Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
    Nikolaos Charalampakis
    Sergios Tsakatikas
    Dimitrios Schizas
    Stylianos Kykalos
    Maria Tolia
    Rodanthi Fioretzaki
    Georgios Papageorgiou
    Ioannis Katsaros
    Ahmed Adel Fouad Abdelhakeem
    Matheus Sewastjanow-Silva
    Jane E Rogers
    Jaffer A Ajani
    [J]. World Journal of Gastrointestinal Oncology, 2022, 14 (01) : 181 - 202
  • [8] Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
    Charalampakis, Nikolaos
    Tsakatikas, Sergios
    Schizas, Dimitrios
    Kykalos, Stylianos
    Tolia, Maria
    Fioretzaki, Rodanthi
    Papageorgiou, Georgios
    Katsaros, Ioannis
    Abdelhakeem, Ahmed Adel Fouad
    Sewastjanow-Silva, Matheus
    Rogers, Jane E.
    Ajani, Jaffer A.
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (01) : 181 - 202
  • [9] Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
    Chen, Cong
    Zhang, Fan
    Zhou, Ning
    Gu, Yan-Mei
    Zhang, Ya-Ting
    He, Yi-Di
    Wang, Ling
    Yang, Lu-Xi
    Zhao, Yang
    Li, Yu-Min
    [J]. ONCOIMMUNOLOGY, 2019, 8 (05):
  • [10] Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway
    Cheng, Runzi
    Li, Baizhi
    Wang, Huaiming
    Zeng, Yongming
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (11): : 3122 - 3138